Here is the talk I gave on March 3rd 2025 at the CRUK Cambridge Institute. Thanks again to Dr. Henno Martin and the team for the invitation and the great discussions on novel adjuvant therapies!
Great. I tried it. Indeed more than twice as many censored patients censored on the experimental arm, but to my surprise HR Upper limit CI does not cross 1 unless 75% of censored events in experimental arm are modified for toxicity at 15 months. That looks like a fairly stable results. Maybe there is a true PFS benefit to Ami Lazer.... Will see what the OS will look like. Thanks again! Cool app
This is great stuff! Any way you can run your censoring app on the Mariposa first line Amivatinib Lazertenib vs osimertinib? I was puzzled why they claim Ami Lazer has a PFS advantage but they end with less people at risk at the 3 month mark in the Ami Lazer arm.
Great. I tried it. Indeed more than twice as many censored patients censored on the experimental arm, but to my surprise HR Upper limit CI does not cross 1 unless 75% of censored events in experimental arm are modified for toxicity at 15 months. That looks like a fairly stable results. Maybe there is a true PFS benefit to Ami Lazer.... Will see what the OS will look like. Thanks again! Cool app
to be honest, I'm not suprised by a PFS benefit when adding a drug.
This paper, entitled "Combining drugs and extending treatment - a PFS end point is not sufficient" is really nice : https://pubmed.ncbi.nlm.nih.gov/28534528/
Thanks for using the app and the feedback !
This is great stuff! Any way you can run your censoring app on the Mariposa first line Amivatinib Lazertenib vs osimertinib? I was puzzled why they claim Ami Lazer has a PFS advantage but they end with less people at risk at the 3 month mark in the Ami Lazer arm.
Got to be informative censoring
Uploaded on the app, you can explore it!
Thanks, I’ll try to do that soon!